TS
VRTX icon

Triglav Skladi’s Vertex Pharmaceuticals VRTX Stock Holding History

Triglav Skladi’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Hold
3,450
– – 0.09% 113
2026
Q1 		$1.54M Hold
3,450
– – 0.11% 102
2025
Q4 		$1.56M Hold
3,450
– – 0.1% 103
2025
Q3 		$1.35M Hold
3,450
– – 0.09% 97
2025
Q2 		$1.54M Hold
3,450
– – 0.11% 92
2025
Q1 		$1.67M Hold
3,450
– – 0.14% 79
2024
Q4 		$1.39M Buy
+3,450
New +$1.6M 0.11% 94

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Triglav Skladi's VRTX Position: Q2 2026 in Review

Triglav Skladi held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 3,450 shares worth $1.71M. The position accounts for 0.09% of the portfolio, ranked #113.

Triglav Skladi first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Triglav Skladi held 3,450 shares of Vertex Pharmaceuticals worth $1.71M as of Q2 2026.
  • Triglav Skladi left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.09% of Triglav Skladi's portfolio in Q2 2026, its #113 holding.
  • Triglav Skladi first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Triglav Skladi's 13F filing for Q2 2026, filed 11 Aug 2026.